Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study
…, L Guillevin, P Carpentier, E Diot… - Arthritis & …, 2005 - Wiley Online Library
Objective Screening allows for early management of pulmonary arterial hypertension (PAH),
a severe complication of systemic sclerosis (SSc). Since no consensus has been reached …
a severe complication of systemic sclerosis (SSc). Since no consensus has been reached …
Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies
…, P Caramaschi, K Tiev, S Cappelli, E Diot… - The Journal of …, 2010 - jrheum.org
Objective. To measure the prevalence of different types of pulmonary hypertension (PH) and
to identify patients with systemic sclerosis (SSc) at highest risk in a multicenter European …
to identify patients with systemic sclerosis (SSc) at highest risk in a multicenter European …
Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin
…, J Sibilia, L Servais, O Fain, C Larroche, E Diot… - Medicine, 2014 - journals.lww.com
Necrotizing autoimmune myopathy (NAM) is a group of acquired myopathies characterized
by prominent myofiber necrosis with little or no muscle inflammation. Recently, researchers …
by prominent myofiber necrosis with little or no muscle inflammation. Recently, researchers …
Pulmonary manifestations of Sjögren's syndrome
…, A Bigot, B Chaigne, H Henique, E Diot… - European …, 2016 - Eur Respiratory Soc
In 9–20% of cases, Sjögren's syndrome is associated with various respiratory symptoms. The
most typical manifestations are chronic interstitial lung disease (ILD) and tracheobronchial …
most typical manifestations are chronic interstitial lung disease (ILD) and tracheobronchial …
[HTML][HTML] Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis
…, N Hunzelmann, K Tiev, P Caramaschi, E Diot… - PLoS …, 2011 - journals.plos.org
Systemic sclerosis (SSc) is an orphan, complex, inflammatory disease affecting the immune
system and connective tissue. SSc stands out as a severely incapacitating and life-…
system and connective tissue. SSc stands out as a severely incapacitating and life-…
Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study
E Hachulla, P Carpentier, V Gressin, E Diot… - …, 2009 - academic.oup.com
Objectives. This longitudinal study investigated survival, risk factors and causes of death in
the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary …
the multicentre ItinérAIR-Sclérodermie cohort of patients with SSc without severe pulmonary …
Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey
…, O Hinschberger, P Rullier, E Diot… - Blood, The Journal …, 2012 - ashpublications.org
Data on the clinical spectrum and therapeutic management of noninfectious mixed
cryoglobulinemia vasculitis (CryoVas) in the era of hepatitis C virus screening are lacking. We …
cryoglobulinemia vasculitis (CryoVas) in the era of hepatitis C virus screening are lacking. We …
The three‐year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France
…, P de Groote, V Gressin, J Sibilia, E Diot… - … : Official Journal of …, 2009 - Wiley Online Library
Objective An algorithm for the detection of pulmonary arterial hypertension (PAH), based on
the presence of dyspnea and the findings of Doppler echocardiographic evaluation of the …
the presence of dyspnea and the findings of Doppler echocardiographic evaluation of the …
The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases
…, G Le Guenno, I Marie, L Benarous, A Lacraz, E Diot… - Medicine, 2013 - journals.lww.com
Type I cryoglobulinemia vasculitis (CryoVas) is considered a life-threatening condition;
however, data on the characteristics and outcome are scarce. To analyze the presentation, …
however, data on the characteristics and outcome are scarce. To analyze the presentation, …
Treatment of systemic necrotizing vasculitides in patients aged Sixty‐Five years or older: results of a multicenter, Open‐Label, randomized controlled trial of …
C Pagnoux, T Quéméneur, J Ninet, E Diot… - Arthritis & …, 2015 - Wiley Online Library
Objective To investigate a new therapeutic strategy, with rapid corticosteroid dose tapering
and limited cyclophosphamide (CYC) exposure, for older patients with systemic necrotizing …
and limited cyclophosphamide (CYC) exposure, for older patients with systemic necrotizing …